Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Pyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | ALPI | P09923 | 1/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 6/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL273314 | 1.00 | NAPRT (0.60) | NAPRTTSHRTDP1CA2CA4 | |
| Pyridine SCHEMBL28548371 | 1.00 | NAPRT (0.60) | NAPRTTSHRTDP1CA2CA4 | |
| Pyridine SCHEMBL28901683 | 1.00 | NAPRT (0.60) | NAPRTTSHRTDP1CA2CA4 | |
| Pyridine SCHEMBL26605130 | 1.00 | NAPRT (0.60) | NAPRTTSHRTDP1CA2CA4 | |
| Pyridine SCHEMBL273312 | 1.00 | NAPRT (0.60) | NAPRTTSHRTDP1CA2CA4 | |
| Benzene SCHEMBL2367770 | 1.00 | NAPRT (0.60) | NAPRTTSHRTDP1CA2CA4 | |
| Pyridine SCHEMBL15647489 | 0.97 | TSHR (0.56) | NAPRTTSHRTDP1CA2CA4 | |
| Pyridine SCHEMBL28958471 | 0.97 | TSHR (0.56) | NAPRTTSHRTDP1CA2CA4 | |
| Pyridine SCHEMBL1652035 | 0.97 | TSHR (0.56) | NAPRTTSHRTDP1CA2CA4 | |
| Pyridine SCHEMBL27510816 | 0.97 | TSHR (0.56) | NAPRTTSHRTDP1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025098503-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | 甘李药业股份有限公司 | 2025-05-15 | — | — | WO | disclosed |
| CN-110664655-B | Cell culture solution | 西安博和医疗科技有限公司 | 2023-02-28 | — | — | CN | disclosed |
| CN-113774036-B | Imine reductase mutant and application thereof | 迪嘉药业集团有限公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-114533658-A | Composition for treating premature ejaculation by SS-PE and preparation method thereof | 郭建芳 | 2022-05-27 | — | — | CN | disclosed |
| CN-113354702-B | Separation and purification process of high-purity NADP | 杭州唯泰生物药业有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-111705099-B | Preparation method of (S) -1- (3, 5-dichloropyridine-4-substituted) ethanol | 天津药明康德新药开发有限公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-109884317-B | Application of oxidized thio-coenzyme I in homogeneous enzyme immunodiagnosis reagent | 杭州博谱医药科技有限公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-113774036-A | Imine reductase mutant and application thereof | 迪嘉药业集团有限公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-113481265-A | Method for preparing NADP by applying biological enzyme method | 合肥康诺生物制药有限公司 | 2021-10-08 | — | — | CN | disclosed |
| CN-113354702-A | Separation and purification process of high-purity NADP | 杭州唯泰生物药业有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-108969524-B | Method for treating postherpetic neuralgia | 中国人民解放军总医院 | 2020-10-30 | — | — | CN | disclosed |
| CN-111705099-A | Preparation method of (S) -1- (3, 5-dichloropyridine-4-substituted) ethanol | 天津药明康德新药开发有限公司 | 2020-09-25 | — | — | CN | disclosed |
| CN-108969525-B | Composition for treating postherpetic neuralgia and preparation method thereof | 中国人民解放军总医院 | 2020-07-28 | — | — | CN | disclosed |
| CN-110664655-A | Cell culture solution | 西安博和医疗科技有限公司 | 2020-01-10 | — | — | CN | disclosed |